RWS Aims to Slash Trial Timelines with Unified, AI-Powered Service

MAIDENHEAD, England – July 14, 2026 – In a move aimed at one of the most persistent bottlenecks in drug development, global AI solutions company RWS has launched a tech-enabled service designed to significantly reduce delays in global clinical trials. The new offering integrates the entire linguistic validation lifecycle for electronic Clinical Outcome Assessments (eCOAs) under a single, unified program, promising to accelerate study timelines and simplify complex operational workflows for pharmaceutical sponsors and clinical research organizations (CROs).

The Fragmentation Bottleneck in Global Trials

Global clinical trials are massive, multi-year undertakings where every week saved can translate into millions of dollars and, more importantly, faster patient access to new therapies. A critical but often underestimated pressure point in these studies is language. Ensuring that patient questionnaires and clinician assessments—known as Clinical Outcome Assessments (COAs)—are accurately and consistently translated and culturally adapted across dozens of languages is a monumental task.

For years, this process has been notoriously fragmented. A typical trial sponsor might juggle separate vendors for licensing the original COA instrument, translating it, validating its linguistic and cultural accuracy, migrating it into an eCOA software platform, and training the clinical raters who administer it. This multi-vendor approach creates a cascade of hand-offs, blurring accountability and narrowing visibility. Small delays at each stage compound, creating significant operational and regulatory risks that can jeopardize study start-up, site activation, and ultimately, regulatory submissions.

Industry analysis reveals that this linguistic validation phase is frequently on the critical path to achieving the "first-patient-in" milestone. A single study using five different COAs across 20 languages could involve managing 100 unique instrument variants, a process that can take months and threaten to derail tightly managed timelines. Furthermore, regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require robust documentation proving that translated instruments are conceptually equivalent. A failure to provide this evidence can lead to entire datasets from specific regions being deemed unreliable, compromising the integrity of the trial's results.

A Unified Model for Speed and Simplicity

RWS's new service directly confronts this fragmentation by redesigning the delivery model. The company has consolidated COA licensing, source validation, multilingual translation, eCOA migration, intelligent workflows, and rater training into a single, integrated program. This is all managed by one dedicated team, providing end-to-end governance and a single point of accountability across the entire COA lifecycle.

By removing these traditional service silos, the model aims to streamline communication, enforce consistent governance, and simplify vendor management for trial sponsors. "Clinical teams shouldn't have to choose between speed and scientific standards," said Dan Herron, Global Vice President, Digital Health at RWS. "For more than a decade, the industry has relied on fragmented delivery models... We've reimagined that approach by bringing every service together under a single program – creating a faster, more connected and more scalable model."

This integrated approach is already gaining traction with key players in the eCOA ecosystem. Martial Marcotti, EVP & Chief Product Officer at the leading eCOA vendor Kayentis, endorsed the new model. "Bringing eCOA translation, linguistic validation and rater training together under one program team is exactly the kind of service model global clinical trials need," Marcotti stated. "An integrated approach like this can simplify global study execution, reduce handoffs and help sponsors move faster without compromising endpoint quality, compliance or the patient experience." This partnership between a language technology leader and an eCOA platform provider exemplifies the kind of deep integration needed to smooth out the process from content creation to digital deployment.

The Engine of Innovation: AI and Intelligent Automation

Powering this new, streamlined model is a significant investment in artificial intelligence and smart automation. RWS is leveraging its deep expertise in language technology, including its industry-leading Trados translation platform, to augment its human experts and accelerate delivery without sacrificing quality. The company's proprietary "Cultural Intelligence Layer," which draws on a network of 250,000 language and data specialists, provides the foundation for this tech-enabled approach.

The service utilizes AI-enhanced workflows that incorporate Neural Machine Translation (NMT) to produce high-quality draft translations rapidly. This is followed by a rigorous "human-in-the-loop" process, where expert linguists and subject matter experts focus on verifying medical accuracy, ensuring cultural appropriateness, and confirming regulatory compliance. This hybrid model allows technology to handle repetitive, time-consuming tasks, freeing up human experts to apply their critical thinking to the most nuanced aspects of linguistic validation, such as cognitive debriefing with patients.

Intelligent workflows further automate the process by routing tasks, performing automated quality checks against glossaries and style guides, and providing real-time project visibility. This not only speeds up the validation cycles but also enhances consistency—a critical factor for data integrity. The goal is to automate repetitive tasks and strengthen quality oversight while preserving the scientific rigor that global research demands.

Navigating a Complex Regulatory and Quality Landscape

For any innovation in the clinical trial space to be successful, it must operate within a fortress of regulatory compliance and quality assurance. RWS's integrated model is designed with these strict requirements at its core. The company's processes are aligned with the rigorous guidelines set forth by ISPOR (The Professional Society for Health Economics and Outcomes Research), which are considered the gold standard for COA translation and are recommended by both the FDA and EMA.

The unified digital platform provides a controlled and auditable environment for every step. Each translation, review, and approval is captured in a complete audit trail, providing the transparent documentation required for regulatory submissions. This traceability is crucial for demonstrating that the eCOA instruments used in a trial are valid and conceptually equivalent across all languages and cultures.

Furthermore, the inclusion of rater training within the same program directly addresses a key variable in data quality. By ensuring that the clinicians who administer assessments are trained consistently and effectively on the validated digital instruments, the service helps reduce variability in data collection and strengthens confidence in the trial's endpoints. This holistic view of quality, from initial translation to final data capture, represents a significant step forward in protecting the integrity of global clinical research. By integrating these once-siloed functions, RWS is not just accelerating a process; it is building a more robust framework to ensure the data collected from patients worldwide is both reliable and meaningful.